These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9198122)

  • 1. Viral vector-mediated gene therapy for hemophilia B.
    Eisensmith RC; Woo SL
    Thromb Haemost; 1997 Jul; 78(1):24-30. PubMed ID: 9198122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene transfer as an approach to treating hemophilia.
    High KA
    Semin Thromb Hemost; 2003 Feb; 29(1):107-20. PubMed ID: 12640573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
    Herzog RW; Mount JD; Arruda VR; High KA; Lothrop CD
    Mol Ther; 2001 Sep; 4(3):192-200. PubMed ID: 11545609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy for hemophilia: clinical trials and technical tribulations.
    Viiala NO; Larsen SR; Rasko JE
    Semin Thromb Hemost; 2009 Feb; 35(1):81-92. PubMed ID: 19308896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects.
    Hasbrouck NC; High KA
    Gene Ther; 2008 Jun; 15(11):870-5. PubMed ID: 18432276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
    High KA
    Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AAV vectors for hemophilia B gene therapy.
    Chao H; Walsh CE
    Mt Sinai J Med; 2004 Oct; 71(5):305-13. PubMed ID: 15543431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implantation of autologous skin fibroblast genetically modified to secrete clotting factor IX partially corrects the hemorrhagic tendencies in two hemophilia B patients.
    Qiu X; Lu D; Zhou J; Wang J; Yang J; Meng P; Hsueh JL
    Chin Med J (Engl); 1996 Nov; 109(11):832-9. PubMed ID: 9275366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards gene therapy for haemophilia B using primary human keratinocytes.
    Gerrard AJ; Hudson DL; Brownlee GG; Watt FM
    Nat Genet; 1993 Feb; 3(2):180-3. PubMed ID: 8499952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic plasma concentrations of human factor IX in mice after gene delivery into the amniotic cavity: a model for the prenatal treatment of haemophilia B.
    Schneider H; Adebakin S; Themis M; Cook T; Douar AM; Pavirani A; Coutelle C
    J Gene Med; 1999; 1(6):424-32. PubMed ID: 10753068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
    Fields PA; Arruda VR; Armstrong E; Chu K; Mingozzi F; Hagstrom JN; Herzog RW; High KA
    Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors.
    Snyder RO; Miao C; Meuse L; Tubb J; Donahue BA; Lin HF; Stafford DW; Patel S; Thompson AR; Nichols T; Read MS; Bellinger DA; Brinkhous KM; Kay MA
    Nat Med; 1999 Jan; 5(1):64-70. PubMed ID: 9883841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards gene therapy for hemophilia B.
    Anson DS; Hock RA; Austen D; Smith KJ; Brownlee GG; Verma IM; Miller AD
    Mol Biol Med; 1987 Feb; 4(1):11-20. PubMed ID: 3475525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy for haemophilia B.
    Tuddenham E
    Haemophilia; 2012 Jul; 18 Suppl 4():13-7. PubMed ID: 22726076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adeno-associated virus-mediated gene transfer of factor IX for treatment of hemophilia B by gene therapy.
    Herzog RW; High KA
    Thromb Haemost; 1999 Aug; 82(2):540-6. PubMed ID: 10605748
    [No Abstract]   [Full Text] [Related]  

  • 16. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
    Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA
    Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Technology evaluation: AAV factor IX gene therapy, Avigen Inc.
    Fabb SA; Dickson JG
    Curr Opin Mol Ther; 2000 Oct; 2(5):601-6. PubMed ID: 11249763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical and clinical gene therapy for haemophilia.
    Chuah MK; Collen D; Vandendriessche T
    Haemophilia; 2004 Oct; 10 Suppl 4():119-25. PubMed ID: 15479384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy for hemophilia.
    Lynch CM
    Curr Opin Mol Ther; 1999 Aug; 1(4):493-9. PubMed ID: 11713765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.
    Kay MA; Manno CS; Ragni MV; Larson PJ; Couto LB; McClelland A; Glader B; Chew AJ; Tai SJ; Herzog RW; Arruda V; Johnson F; Scallan C; Skarsgard E; Flake AW; High KA
    Nat Genet; 2000 Mar; 24(3):257-61. PubMed ID: 10700178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.